Wednesday July 27, 2016 9:00PM EDT
Malignant Pleural Mesothelioma (MPM) remains one of the most intractable malignancies with current overall survival (OS) of about 12 months in unresectable advanced stages. Multimodality therapy in resectable patients yields median OS of 17-25 months. Recently, the field has made several advances due to novel discoveries and initiatives in epidemiology, screening/detection and treatment.
July 7, 2016 6:00PM CEST
This program will review radiation therapy for lung cancer highlights from the recent 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The focus of the presentations are upon the most relevant data and reports that impact current standards of care in the radiotherapeutic management of non-small cell lung cancer (NSCLC).
July 5, 2016 at 6:00 PM CEST
Patients harboring EGFR mutations represent a subgroup of non-small cell lung cancer (NSCLC) with high sensitivity to EGFR-Tyrosine kinase inhibitors. Many agents are currently available in clinical practice with small differences in terms of efficacy and toxicity profile.
June 30, 2016 9:00PM EDT
"Implementing smoking cessation in lung cancer screening settings: Opportunities and Challenges"
June 28, 2016 at 9:00 PM EDT
This live session of IASLC Lung Cancer Grand Rounds features Dr. Mark Socinski. Dr. Socinski will highlight recent data in lung cancer, presented during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The program will focus on scientific and clinical progress most likely to impact the current management of patients with lung cancer.
June 23, 2016 at 7:00PM Central European Summer Time
This presentation will provide an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer". Available data with bevacizumab - containing regimens in patients with advanced non squamous NSCLC - will be briefly reviewed.
Thursday May 26, 2016 6:00PM Central European Summer Time
This program will review radiation therapy for lung cancer highlights from the recent 2016 European Lung Cancer Conference (ELCC) and European Society for Radiotherapy & Oncology (ESTRO) meetings.
Wednesday, May 11, 2016 at 7 p.m. Central European Summer Time
Although patients with oncogenic-addicted NSCLC respond to targeted therapies, invariably all became refractory to the treatment as a consequence of acquired resistance. Identification of molecular mechanisms responsible for therapy failure is of crucial relevance and many new agents and strategies are currently under development.
Launch: April 18, 2016; Termination: April 17, 2019
INTERNET ENDURING MATERIAL